Disease Areas
Kidney Disease
Kidney Disease
Kidney disease affects the functions of the kidney, impacting the organ’s ability to filter blood, extra water and waste out of a person’s system. These conditions can be chronic or acute.1
Our Approach
Through our acquisition of Human Immunology Biosciences (HI-Bio) in July 2024, we officially entered the nephrology space with a portfolio of investigational drugs that target immune-mediated diseases with serious unmet need. By leveraging our expertise in immunology, clinical development, and commercialization capabilities, we hope to bring potential new options to people living with these conditions.
Innovative Research
Building on our strong scientific expertise in immunology, we aim to deliver innovative treatments to patients with unmet needs across a range of rare diseases. We know that kidney disease is characterized by a lack of novel treatments with potentially severe consequences – such as end-stage kidney disease or graft failure. For this reason, we are initially focused on addressing three rare kidney diseases with serious unmet needs, including late antibody-mediated rejection in kidney transplant recipients, immunoglobulin A nephropathy, and primary membranous nephropathy.
Living with Kidney Disease: Juan Carlos’ Story
When Juan Carlos turned 30, his kidneys stopped working and he had to get a kidney transplant. He explains the challenges he’s overcome and how he now enjoys his day-to-day life. “To drink a cup of coffee in the morning, to be with my family, to be with my dogs. The fact that you have a normal life, and you can do whatever you want, it’s priceless.”
Now, working for Biogen, he’s proud to be part of the story that can help people living with kidney disease.
This is Juan Carlos’ experience and may not be generalizable to other people who have had/undergone a kidney transplant.
Clinical Trials
Biogen conducts clinical trials in kidney disease related to the investigational drugs in our pipeline to evaluate the efficacy and safety of potential medicines.
View all recruiting Biogen clinical trials in kidney disease
Deciding to participate in a clinical trial requires careful consideration. In most cases, the drugs investigated in clinical trials are not yet approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). The benefits and risks of taking the drug are not completely known. By volunteering for a clinical trial, you are helping the medical community determine whether new treatments are safe and effective.
Learn more about clinical trials and access programs
Facts and Figures
~23k
Approximately 23,000 people are living with Antibody-Mediated Rejection in the U.S.2
~36k
It is estimated that there are 36,000 people living with Primary Membranous Nephropathy in the U.S.3
~130k
IgA Nephropathy is the most prevalent glomerular disease, estimated to affect ~130k patients in the U.S.4
- https://www.niddk.nih.gov/health-information/kidney-disease
- SRTR; National Institute of Diabetes and Digestive and Kidney Diseases; Department of Health; Hart, Singh. Clin Transplant 2021; Crew. Am J. Transplant. 2016
- Based upon Kanigicherla. Nephrol. Dial. Transplant. 2016; McGrogan. Nephrol Dial Transplant. 2011
- Based upon Kwon. JHEOR. 2021; Jarrick. Am Soc of Neph. 2019;
You may also be interested in
Pipeline
Medicines
Access and Health Equity